These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34199072)

  • 1. Synergistic Meropenem/Vaborbactam Plus Fosfomycin Treatment of KPC Producing
    Oliva A; Curtolo A; Volpicelli L; Cogliati Dezza F; De Angelis M; Cairoli S; Dell'Utri D; Goffredo BM; Raponi G; Venditti M
    Antibiotics (Basel); 2021 Jun; 10(7):. PubMed ID: 34199072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ceftazidime/avibactam-resistant meropenem-susceptible KPC-producing Klebsiella pneumoniae: Analysis of cases and evaluation of in vitro activity of fosfomycin-containing combinations.
    Oliva A; Al Ismail D; Arcari G; Miele MC; Casali E; Sacco F; Volpicelli L; De Angelis M; Mascellino MT; Cancelli F; Raponi G; Carattoli A; Venditti M
    J Glob Antimicrob Resist; 2023 Jun; 33():321-327. PubMed ID: 37086891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutations in
    Rogers TM; Kline EG; Griffith MP; Jones CE; Rubio AM; Squires KM; Shields RK
    JAC Antimicrob Resist; 2023 Oct; 5(5):dlad113. PubMed ID: 37901589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Characteristics and Outcome of Ceftazidime/Avibactam-Resistant
    Oliva A; Campogiani L; Savelloni G; Vitale P; Lodi A; Sacco F; Imeneo A; Volpicelli L; Polani R; Raponi G; Sarmati L; Venditti M
    Open Forum Infect Dis; 2023 Jul; 10(7):ofad327. PubMed ID: 37476077
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Compassionate use of meropenem/vaborbactam for infections caused by KPC-producing
    Tumbarello M; Raffaelli F; Cascio A; Falcone M; Signorini L; Mussini C; De Rosa FG; Losito AR; De Pascale G; Pascale R; Giacobbe DR; Oliva A; Farese A; Morelli P; Tiseo G; Meschiari M; Del Giacomo P; Montagnani F; Fabbiani M; Vargas J; Spanu T; Bassetti M; Venditti M; Viale P
    JAC Antimicrob Resist; 2022 Mar; 4(1):dlac022. PubMed ID: 35265842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bloodstream infection caused by KPC-producing Klebsiella pneumoniae resistant to ceftazidime/avibactam: epidemiology and genomic characterization.
    Gaibani P; Re MC; Campoli C; Viale PL; Ambretti S
    Clin Microbiol Infect; 2020 Apr; 26(4):516.e1-516.e4. PubMed ID: 31740422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro antibacterial activity of ceftazidime/avibactam in combination against planktonic and biofilm carbapenemase-producing Klebsiella pneumoniae isolated from blood.
    Papalini C; Sabbatini S; Monari C; Mencacci A; Francisci D; Perito S; Pasticci MB
    J Glob Antimicrob Resist; 2020 Dec; 23():4-8. PubMed ID: 32810638
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and Efficacy of Ceftazidime-Avibactam in the Treatment of Experimental Pneumonia Caused by Klebsiella pneumoniae Carbapenemase-Producing K. pneumoniae in Persistently Neutropenic Rabbits.
    Petraitiene R; Petraitis V; Kavaliauskas P; Maung BBW; Khan F; Naing E; Aung T; Zigmantaite V; Grigaleviciute R; Kucinskas A; Stakauskas R; Georgiades BN; Mazur CA; Hayden JA; Satlin MJ; Walsh TJ
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015048
    [No Abstract]   [Full Text] [Related]  

  • 9. Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-, Cefiderocol-Resistant ST-512
    Tiseo G; Falcone M; Leonildi A; Giordano C; Barnini S; Arcari G; Carattoli A; Menichetti F
    Open Forum Infect Dis; 2021 Jun; 8(6):ofab141. PubMed ID: 34189161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activity of Ceftazidime-Avibactam Alone and in Combination with Ertapenem, Fosfomycin, and Tigecycline Against Carbapenemase-Producing
    Ojdana D; Gutowska A; Sacha P; Majewski P; Wieczorek P; Tryniszewska E
    Microb Drug Resist; 2019 Nov; 25(9):1357-1364. PubMed ID: 31295055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of KPC Variant and Porin Genotype on the
    Wilson WR; Kline EG; Jones CE; Morder KT; Mettus RT; Doi Y; Nguyen MH; Clancy CJ; Shields RK
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30617090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
    Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
    Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing
    Gaibani P; Lombardo D; Bussini L; Bovo F; Munari B; Giannella M; Bartoletti M; Viale P; Lazzarotto T; Ambretti S
    Antibiotics (Basel); 2021 May; 10(5):. PubMed ID: 34066420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and Predictors of Mortality in Patients With KPC-Kp Infections Treated With Meropenem Vaborbactam: An Observational Multicenter Study.
    Tumbarello M; Raffaelli F; Giannella M; De Pascale G; Cascio A; De Rosa FG; Cattelan AM; Oliva A; Saracino A; Bassetti M; Mussini C; Luzzati R; Capone A; Signorini L; Bartoletti M; Sambo M; Sarmati L; Antinori S; Mularoni A; Tascini C; Corona A; Pascale R; Rubino R; Corcione S; Mazzitelli M; Giuliano G; Lovecchio A; Bavaro DF; Meschiari M; Montagnani F; Fabbiani M; De Benedetto I; Antonelli M; Venditti M; Viale P
    Open Forum Infect Dis; 2024 Jun; 11(6):ofae273. PubMed ID: 38854388
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Huang Y; Wu T; Perez O; Rana AP; Chen L; Kreiswirth BN; Satlin MJ; Bulman ZP
    Front Microbiol; 2021; 12():618087. PubMed ID: 33763041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam.
    Galani I; Antoniadou A; Karaiskos I; Kontopoulou K; Giamarellou H; Souli M
    Clin Microbiol Infect; 2019 Jun; 25(6):763.e5-763.e8. PubMed ID: 30928562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae.
    Romanelli F; De Robertis A; Carone G; Dalfino L; Stufano M; Del Prete R; Mosca A
    New Microbiol; 2020 Jul; 43(3):136-138. PubMed ID: 32596740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of ceftazidime/avibactam plus fosfomycin combination on 30 day mortality in patients with bloodstream infections caused by KPC-producing
    Oliva A; Volpicelli L; Di Bari S; Curtolo A; Borrazzo C; Cogliati Dezza F; Cona A; Agrenzano S; Mularoni A; Trancassini M; Mengoni F; Stefani S; Raponi G; Venditti M
    JAC Antimicrob Resist; 2022 Dec; 4(6):dlac121. PubMed ID: 36506890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
    Tsivkovski R; Lomovskaya O
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 32015028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thoracic aorta graft infection by avibactam-resistant KPC-producing
    Belati A; Novara R; Bavaro DF; Procopio A; Fico C; Diella L; Romanelli F; Stolfa S; Mosca A; Di Gennaro F; Saracino A
    Infez Med; 2022; 30(2):277-284. PubMed ID: 35693053
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.